Chronic lymphocytic leukemia (CLL) is the most common form of leukemia found in adults in Western countries, though it is extremely rare in Asian countries such as China and Japan. Can you properly identify the markers, differentials, and treatment indications?
Introduction: Chronic lymphocytic leukemia (CLL), a type of non‐Hodgkin lymphoma, is the most common type of leukemia in adults and can be indolent or aggressive in nature. Hematologists/oncologists (hem/oncs) need to be competent treating this disease in order to optimize patient outcomes. ...
Recommended Clinical Quiz Time! Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia 0.25 CME / LOC / MOC Credit Credits Diseases & Conditions Kearns-Sayre Syndrome Find Us On About About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center ...
In reflecting on the narrow range of treatment options available to his first patient, such as chlorambucil and vincristine, and later, combination therapies such as bendamustine-rituximab, Bruce Cheson, MD, characterizes the jump from chemotherapy-based courses to more recent, targeted regimens compose...
Viruses are obligate intracellular pathogens that cause infection in susceptible host cells. Virus infections could be lytic, chronic, latent or immortalizing. Viruses causing latent infection are associated with high morbidity and mortality worldwide. T
The FDA has granted accelerated approval of ofatumumab intravenous infusion for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Ibrutinib is a first-in-class oral, covalent inhibitor of Bruton's tyrosine kinase (BTK). It was first approved in 2013 for treatment of patients with mantle cell lymphoma. It has since been approved for use in patients with pretreated chronic lymphocytic leukemia (CLL), and in CLL patients...